Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × NIH × Midazolam × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1 Completed 1

Sponsor Class

INDUSTRY 3 NIH 1 FED 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Fatigue 1

Interventions

Cyclophosphamide 40 aldesleukin 24 fludarabine phosphate 22 fludarabine 21 Carboplatin 16 Rituximab 15 Bevacizumab 15 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 14 Cisplatin 13 Radiotherapy 12 Interleukin-2 12 Bortezomib 12 Paclitaxel 11 Leucovorin 11 Etoposide 11 Erlotinib Hydrochloride 11 Oxaliplatin 10 Magnetic Resonance Spectroscopy 10 Fluorouracil 10 Filgrastim 10 Doxorubicin 10 Sorafenib 9 Dexamethasone 9 Biopsy 9 Vincristine 8 Radiation 8 Docetaxel 8 Capecitabine 8 tanespimycin 7 cediranib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02317341 2019-03-20

Effect of Ketamine on Fatigue Following Cancer Therapy

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡